Bogatkevich, G. S., Highland, K. B., Akter, T., & Silver, R. M. (2012). The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects. Hindawi Publishing Corporation.
Citación estilo ChicagoBogatkevich, Galina S., Kristin B. Highland, Tanjina Akter, and Richard M. Silver. The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects. Hindawi Publishing Corporation, 2012.
Cita MLABogatkevich, Galina S., Kristin B. Highland, Tanjina Akter, and Richard M. Silver. The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects. Hindawi Publishing Corporation, 2012.